These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8761126)

  • 21. A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient.
    Botticelli A; Onesti CE; Strigari L; Occhipinti M; Di Pietro FR; Cerbelli B; Petremolo A; Anselmi E; Macrini S; Roberto M; Falcone R; Lionetto L; Borro M; Milano A; Gentile G; Simmaco M; Marchetti P; Mazzuca F
    Anticancer Drugs; 2017 Jun; 28(5):551-556. PubMed ID: 28296649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Limited 5-fluorouracil-induced systemic scleroderma].
    Benomar S; Boutayeb S; Benzekri L; Senouci K; Errihani H; Hassam B
    Ann Dermatol Venereol; 2009 Nov; 136(11):816-8. PubMed ID: 19917437
    [No Abstract]   [Full Text] [Related]  

  • 23. Interstitial lung diseases in patients treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX).
    Jung KH; Kil SY; Choi IK; Seo JH; Shin C; Kim YS; Kim JH
    Int J Tuberc Lung Dis; 2006 Oct; 10(10):1181-2. PubMed ID: 17044215
    [No Abstract]   [Full Text] [Related]  

  • 24. Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
    Meropol NJ; Rustum YM; Creaven PJ; Blumenson LE; Frank C
    Cancer Invest; 1999; 17(1):1-9. PubMed ID: 10999043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Will we ever be ready for blood level-guided therapy?
    Walko CM; McLeod HL
    J Clin Oncol; 2008 May; 26(13):2078-9. PubMed ID: 18445837
    [No Abstract]   [Full Text] [Related]  

  • 26. 5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer.
    Jodrell DI; Stewart M; Aird R; Knowles G; Bowman A; Wall L; McLean C
    Br J Cancer; 2001 Mar; 84(5):600-3. PubMed ID: 11237378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer chronotherapy: principles, applications, and perspectives.
    Vincenzi B; Santini D; La Cesa A; Tonini G
    Cancer; 2003 Aug; 98(4):881-2; author reply 882-3. PubMed ID: 12910534
    [No Abstract]   [Full Text] [Related]  

  • 28. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
    Okuda H; Ogura K; Kato A; Takubo H; Watabe T
    J Pharmacol Exp Ther; 1998 Nov; 287(2):791-9. PubMed ID: 9808711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Translating preclinical hopes into clinical reality for children with ependymoma.
    Grill J
    Neuro Oncol; 2015 Dec; 17(12):1545-6. PubMed ID: 26468169
    [No Abstract]   [Full Text] [Related]  

  • 30. Phenytoin toxicity as a result of 5-fluorouracil administration.
    Rosemergy I; Findlay M
    N Z Med J; 2002 Aug; 115(1159):U124. PubMed ID: 12362168
    [No Abstract]   [Full Text] [Related]  

  • 31. Unresectable liver metastases from colorectal cancer and hepatic arterial infusion chemotherapy: how, when and to whom?
    Viúdez A; Rodríguez J; Gil-Bazo I
    Cardiovasc Intervent Radiol; 2009 May; 32(3):603-4. PubMed ID: 19194743
    [No Abstract]   [Full Text] [Related]  

  • 32. [Systemic palliative chemotherapy with 5-fluorouracil and leucovorin in disseminated colorectal cancer].
    Wiboltt K; Raskov HH
    Ugeskr Laeger; 1999 Jun; 161(25):3827-32. PubMed ID: 10412300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.
    Lee A; Ezzeldin H; Fourie J; Diasio R
    Clin Adv Hematol Oncol; 2004 Aug; 2(8):527-32. PubMed ID: 16163233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variability in fluorouracil exposure during continuous intravenous infusion.
    Hendrayana T; Kurth V; Krolop L; Kenny P; Hilger RA; Schmidt-Wolf IG; Ko YD; Jaehde U
    Int J Clin Pharmacol Ther; 2012 Jan; 50(1):82-4. PubMed ID: 22192656
    [No Abstract]   [Full Text] [Related]  

  • 35. Reversible findings of restricted diffusion in 5-fluorouracil neurotoxicity.
    Lucato LT; McKinney AM; Short J; Teksam M; Truwit CL
    Australas Radiol; 2006 Aug; 50(4):364-8. PubMed ID: 16884425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Therapeutic advances in digestive oncology. III. Chemotherapy of digestive system cancers].
    Zeitoun P; Martin F; Nasca S
    Med Chir Dig; 1979; 8(7):655-60. PubMed ID: 94142
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacokinetic adaptation of 5-fluorouracil: where are we and where are we going?
    Boisdron-Celle M
    Pharmacogenomics; 2012 Oct; 13(13):1437-9. PubMed ID: 23057541
    [No Abstract]   [Full Text] [Related]  

  • 38. Analysis of microdialysates from cancer patients by capillary electrophoresis.
    Mader RM; Brunner M; Rizovski B; Mensik C; Steger GG; Eichler HG; Müller M
    Electrophoresis; 1998 Nov; 19(16-17):2981-5. PubMed ID: 9870399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of 5-fluorouracil applicability by the collagen gel droplet embedded drug sensitivity test with area under the curve analysis.
    Ochiai T; Nishimura K; Noguchi H; Watanabe T; Kitajima M; Konishi N; Sato G; Nagaoka I; Futagawa S
    Anticancer Drugs; 2007 Jan; 18(1):17-21. PubMed ID: 17159498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer Treatment Group study.
    Burch PA; Block M; Schroeder G; Kugler JW; Sargent DJ; Braich TA; Mailliard JA; Michalak JC; Hatfield AK; Wright K; Kuross SA
    Clin Cancer Res; 2000 Sep; 6(9):3486-92. PubMed ID: 10999733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.